Avoro Capital Advisors Adds $124M in Definium Therapeutics, Inc. ($DFTX)

Avoro Capital Advisors has taken a new position in DFTX by acquiring 5 million shares. This move, detailed in their latest 13F filing with the SEC, places the value of their stake at approximately $123.75 million. The shares were bought at a cost basis of $17.40 each.

What Changed in Avoro Capital Advisors' DFTX Position

Avoro Capital Advisors' 13F filing shows a new buy of 5 million DFTX shares, valued at about $123.75 million. This represents a fresh investment as they previously held no shares in the company.

Other Institutional Activity in DFTX

In addition to Avoro's new position, other institutional investors have also been active in DFTX. BlackRock, Inc. added 8,480,230 shares, bringing its total to 8,480,230 shares worth around $160.28 million. Driehaus Capital Management LLC trimmed its holdings by 625,313 shares, leaving it with 5,911,889 shares valued at $111.73 million. Janus Henderson Group PLC acquired 3,556,041 shares, now holding shares worth about $67.23 million. Deep Track Capital, LP also entered with 3 million shares, valuing its stake at $56.7 million.

Definium Therapeutics, Inc. Stock Down 39.6%

Shares of DFTX traded near $24.75. The stock has garnered attention from analysts, with price targets ranging from $25 to as high as $70, reflecting varied expectations for the company's performance.

Insider Buying and Selling at Definium Therapeutics, Inc.

Recent insider transactions at DFTX included both buying and selling. On February 3, 2026, CEO Robert Barrow bought 320,000 shares, while Chief Legal Officer Mark Sullivan and Chief Commercial Officer Matthew Wiley acquired 125,000 and 115,000 shares, respectively. These purchases were not part of a pre-planned trading program. Later, on March 25, 2026, planned sales were made by several insiders, including 24,431 shares by CEO Barrow and 10,702 shares by CLO Sullivan, at an average price of $18.47.

Analysts Set New Price Targets

Analysts have been active with their assessments of DFTX. On May 8, 2026, Piper Sandler maintained its 'buy' rating with a $48 price target. Earlier, on April 22, Leerink Partners also kept a 'buy' rating, setting a target at $30. Stifel initiated coverage with a 'buy' rating and a $30 target on April 17. The consensus among analysts is positive, with a mean target price of $40.57 based on multiple buy ratings.

About DFTX

DFTX operates in the [sector] industry, focusing on [specific business activities]. Headquartered in [location], the company is led by CEO [name] and employs approximately [number] people. DFTX is known for its [product/service] offerings and continues to expand its presence in the market.

Bottom Line

Avoro Capital Advisors' new position in DFTX highlights growing institutional interest in the company. While this 13F filing reflects holdings as of the reporting period, it underscores the fund's strategic move into DFTX. Investors often track such filings for insights into institutional strategies, though these reports are backward-looking and may not represent current positions.